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Background: A new histopathological classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated
glomerulonephritis was recently proposed. We evaluated the predictive value of this classification for renal outcome
in Japanese patients.
Methods: We enrolled 122 patients with ANCA-associated glomerulonephritis diagnosed at several institutions in Japan
between January 2000 and March 2010. Twenty patients were excluded because of observation durations of <1 year,
and/or because their biopsy specimens contained <10 glomeruli. Renal biopsy specimens were categorized into four
classes according to the proposed classification. We evaluated the predictive value of immunohistochemical staining for
α-smooth muscle actin (SMA), Wilm’s tumor 1 (WT1), CD68, and cytokeratin for end-stage renal disease (ESRD).
Results: The study population included 54 men and 48 women. Age, estimated glomerular filtration rate (eGFR), and
proteinuria were 66.3 ± 11.3 years, 21.6 ml/min. and 1.10 g/24 h, respectively. Eighty-six patients were positive for
myeloperoxidase-ANCA, five were positive for proteinase 3-ANCA, and 11 were negative for both antibodies. Median
follow-up time was 41.0 months. Twenty-three patients (22.5%) developed ESRD during the follow-up period. Twelve
patients died during follow up; 7/12 patients developed ESRD before death, and 5/12 patients died without ESRD. The
incidence of ESRD increased with sequential categories: focal, 2/46 (4.3%); crescentic, 9/32 (28%); mixed, 8/18 (44%);
and sclerotic, 4/6 (67%). The focal class had the best renal survival and the sclerotic class had the worst renal
survival (p < 0.001). Kaplan-Meier renal survival analysis was similar to that of the new classification system proposal.
In the multivariate analysis, the classification system tended to be a prognostic factor for ESRD (p = 0.0686, crescentic,
mixed and sclerotic vs. focal, hazard ratio (HR) [95% confidence interval, CI]; 2.99 [0.61–22.7], 5.04 [1.11–36.4] and 9.93
[1.53–85.7], respectively). α-SMA-positivity also tended to be associated with ESRD (p = 0.1074).
Conclusion: The new histopathological classification was associated with eGFR at 1 year and tended to be associated
with ESRD in our Japanese cohort with ANCA-associated glomerulonephritis. α-SMA positivity might be an additional
prognostic factor for ESRD.
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Anti-neutrophil cytoplasmic antibody (ANCA)-associated
glomerulonephritis is a common cause of rapidly progres-
sive glomerulonephritis in adults [1]. Three major categor-
ies have been defined: microscopic polyangiitis (MPA),
granulomatosis with polyangiitis (GPA), and eosinophilic
granulomatosis with polyangiitis (EGPA) [2,3]. The histo-
pathological findings are characterized by various lesions,
particularly extracapillary proliferation and fibrinoid necro-
sis; however, lesions such as fibrous crescent formation
and focal or global glomerular sclerosis, indicating chronic
lesions, are also observed [4]. The renal prognosis of
ANCA-associated glomerulonephritis differs greatly be-
tween individual patients. Several studies have determined
the clinical and histopathological predictors of renal out-
come, and shown that low levels of serum creatinine (SCr)
at diagnosis and a high percentage of normal glomeruli
were predictors for a better renal outcome, whereas a high
percentage of sclerotic glomeruli was a predictor for a
worse renal outcome [5–8]. However, a standardized histo-
pathological classification of this disease has been lacking
for many years.
A histopathological classification of ANCA-associated
glomerulonephritis was recently proposed, based on an
analysis of 100 patients from multiple centers in Europe
[9]. This classification system is based on glomerular
pathology and defines four classes: focal, crescentic,
mixed and sclerotic. The authors reported that the
phenotypic order of the class corresponded to progres-
sive worsening of renal function. Japanese patients with
ANCA-associated vasculitis show a different distribu-
tion of ANCA subtypes compared with patients from
Western countries, with higher rates of myeloperoxidase
(MPO)-ANCA expression than proteinase 3 (PR3)-ANCA
[10,11]. We therefore performed a validation study to
determine whether this proposed histopathological classifi-




We enrolled 122 patients diagnosed with biopsy-confirmed
ANCA-associated glomerulonephritis between January
2000 and March 2010 from six institutions in Japan
(Miyazaki University, Kanazawa University, Toyama Pre-
fectural Central Hospital, Miyazaki Prefectural Hospital,
Koga General Hospital and Miyazaki Social Insurance
Konan Hospital). Patients with primary renal vasculitis
were defined in accordance with the following criteria:
new patients with MPA, GPA, EGPA or renal limited
vasculitis (RLV) and renal involvement (elevated SCr,
hematuria, proteinuria, or red cell casts) attributable to
active vasculitis with or without other organ involvement,
and positive serology for ANCA. Histological confirmationof renal involvement was the finding of necrotizing vascu-
litis and pauci-immune crescentic glomerulonephritis in
the renal biopsy. The European Medicines Agency (EMEA)
algorithm [12] was used to define MPA, GPA and EGPA.
This algorithm utilizes the American College of Rheuma-
tology criteria (1990) and the Chapel Hill Consensus Con-
ference definitions. Using this approach, RLV is placed
within MPA. ANCA-negative patients were eligible for
enrollment in this study if there was histological confirm-
ation of renal involvement. Patients who were followed
up for <1 year (n = 14) or whose biopsy specimens
contained <10 glomeruli (n = 6) were excluded. A total of
102 patients were therefore included in this study.
Most of the patients received intravenous and/or oral
methylprednisolone therapy with or without immuno-
suppressants after diagnosis, according to the attend-
ing physician’s judgement. The ethical committee of
University of Miyazaki approved this study (approval
number: 2010–751).
Treatment
In this present study, 83 (81.4%) cases received methyl-
prednisolone pulse therapy, and 89 (87.3%) cases were
administered oral prednisolone. Furthermore, 30 (29.4%)
cases were treated with cyclophosphamide (CYC): 15
(14.7%) were treated with intravenous CYC pulse ther-
apy (IV-CY), 11 (10.8%) with oral CYC therapy, and four
(3.9%) with both IV-CY and oral CYC. Twenty-one (20.6%)
cases were treated with mizoribine (MZB), three (2.9%)
cases were treated with azathioprine (AZA), and one
(1.0%) case was treated with gusperimus hydrochloride.
Patient parameters and outcomes
This was a retrospective study based on clinical informa-
tion obtained from hospital records and general practice.
SCr and the degree of proteinuria were measured at the
time of renal biopsy, prior to the initiation of immuno-
suppressive therapy or hemodialysis. SCr was evaluated
every 1–3 months after the initiation of therapy. The de-
velopment of ESRD during follow-up was the primary
outcome. ESRD was defined as requiring permanent renal
replacement therapy. Estimated glomerular filtration rate
(eGFR) at 1 year was the secondary outcome.
Calculation of eGFR
SCr was assayed by an enzymatic method and eGFR was
calculated using the following equation [13]: eGFR (ml/
min/1.73 m2) = 194 × age (years)–0.287 × serum creatinine
(mg/dl)–1.094 (× 0.739 for women).
Renal histopathology
Renal biopsy specimens were examined by light micros-
copy and immunofluorescence analysis. For light micros-
copy, tissues were stained with hematoxylin and eosin,
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ver. The median number of glomeruli per biopsy was
19.0 (range 10–61). For immunofluorescence analysis,
sections were incubated with antibodies against IgG,
IgA, IgM, C3, C4, C1q, and fibrinogen, to exclude other
renal diseases. Renal biopsies were categorized into four
classes in accordance with the newly proposed histo-
pathological classification. Samples with ≥50% normal
glomeruli were classified as focal, those with ≥50% cellu-
lar crescentic glomeruli were classified as crescentic, and
those with ≥50% globally sclerotic glomeruli were classi-
fied as sclerotic. The other cases, those with <50% nor-
mal, cellular crescentic, and globally sclerotic glomeruli
were classified as mixed. Two independent nephro-
pathologists (T.I. and K.K.) who were blinded to the pa-
tients’ characteristics performed the histopathological
evaluations and classified the specimens into the four clas-
ses. Inter-observer variation of categorization according to
the new histopathological classification was tested (κ =
0.91). Discrepancies between the observers were resolved
by conference to achieve consensus.
Immunohistochemical analysis
Immunohistochemical staining was performed on samples
from 34 patients with crescentic or mixed class for
α-smooth muscle actin (SMA; myoepithelial marker;
clone: 1A4, mouse monoclonal antibody; Dako, Glostrup,
Denmark), Wilm’s tumor 1 (WT1; podocyte marker; clone:
6F-H2, mouse monoclonal antibody; Dako), CD68 (macro-
phage marker; clone: PG-M1, mouse monoclonal antibody;
Dako) and cytokeratin (epithelial marker; clone: AE1/AE3,
mouse monoclonal antibody; Dako), using 4-μm-thick
sections of formalin-fixed and paraffin-embedded tissue.
Sections were subsequently stained with Envision (Dako).
Horseradish peroxidase activity was visualized using 3,3′-
diaminobenzidine tetrahydrochloride, and counterstaining
with Meyer’s hematoxylin. Of the 50 cases in either the
crescentic or mixed class, 16 cases did not have sufficient
tissue remaining for immunohistochemical analysis.
Immunoreactivity was evaluated by two investigators
unaware of the patients’ characteristics (T.I. and A.Y.). A
cell was considered positive for α-SMA, CD68 and/or
cytokeratin in case of cytoplasmic staining. A cell was con-
sidered positive for WT1 in case of nuclear staining. We
assessed normal glomeruli in each sample and counted all
immunopositive cells. The definition of a normal glomeru-
lus was a glomerulus without collapse, crescent formation,
adhesion, or focal to segmental/global glomerulosclerosis.
Even if the α-SMA-positive area was very small, the
glomerulus was considered to be immunopositive. Repro-
ducibility was assessed by blinded replicate counting of
immunopositive cells performed by the two observers; the
inter-observer correlation coefficients for α-SMA, WT1,
CD68 and cytokeratin were r = 0.86, 0.77, 0.91, 0.87,respectively. Discrepancies between the observers were re-
solved by conference to achieve consensus.
Statistical analysis
Data were analyzed using the Mann–Whitney test, Fisher’s
exact test, and Kruskal-Wallis test and post hoc analysis
(Dunn’s multiple comparison test) as appropriate. Kaplan-
Meier survival analysis was used to compare renal survival.
Multivariate analysis of renal survival was performed by
Cox regression analysis. Patients who died before devel-
oping ESRD were treated as censored in Kaplan-Meier
renal survival analysis and Cox regression analysis. Values
of p < 0.05 were considered to be statistically significant.
JMP 8.0.1 (SAS, Cary, NC, USA) and GraphPad Prism 5.01
(GraphPad Software, San Diego, CA, USA) were used for
statistical analyses.
Results
Clinical and histopathological studies
Overall, 23 patients developed ESRD that required main-
tenance hemodialysis therapy during follow-up [median,
41.0 months, interquartile range (IQR), 20.0–63.8]. The
baseline characteristics at the time of diagnosis for pa-
tients with and without ESRD are shown in Table 1. The
mean age (± standard deviation) was 66.3 ± 11.3 years.
There were 54 males and 48 females. All patients under-
went serologic tests for MPO-ANCA and PR3-ANCA
using enzyme-linked immunosorbent assays. Eighty-six
patients were positive for MPO-ANCA and five patients
were positive for PR3-ANCA; none were positive for
both antibodies. Although 11 patients were negative for
both antibodies, their disease was confirmed by typical
histopathological features and clinical findings. The me-
dian SCr measured at the time of renal biopsy before
starting immunosuppressive therapy or hemodialysis was
1.95 mg/dl (IQR, 1.30–4.15) and the median eGFR was
21.6 ml/min/1.73 m2 (IQR, 11.5–39.5). The median pro-
teinuria was 1.10 g/24 h (IQR, 0.35–2.12) based on 24-h
urine collection. Age, sex, serum albumin and serum
C-reactive protein (CRP) were not significantly different
between patients with or without ESRD. However, eGFR
and 24-h proteinuria at diagnosis did differ significantly be-
tween patients with and without ESRD [eGFR: 25.7 versus
(vs.) 9.0 ml/min/1.73 m2, p < 0.001; proteinuria: 1.8 vs.
0.7 g/24 h, p < 0.01]. According to the EMEA algorithm, 97
cases were classified as MPA, three as GPA and two as
EGPA. Systemic organ involvements were as follow: ear,
nose and throat, six patients (5.9%); respiratory system, 20
patients (19.6%); and nervous system, 12 patients (11.8%).
The 102 patients were then categorized into four classes
according to the newly proposed histopathological classifi-
cation: 46 patients with focal, 32 patients with crescentic,
18 patients with mixed, and six patients with sclerotic class.
The clinical and histopathological findings in the four
Table 1 Patient characteristics at the time of diagnosis
Total (n = 102) Non-ESRD (n = 79) ESRD during follow-up (n = 23) p value
Age (years) 66.3 ± 11.3 66.3 ± 12.2 66.3 ± 7.7 n.s.
Male/female, n 54/48 39/40 15/8 n.s.
MPO-ANCA, n 86 70 16
PR3-ANCA, n 5 4 1
Both negative, n 11 5 6
eGFR (ml/min/1.73 m2) 21.6 (11.5–39.5) 25.7 (17.4–50.4) 9.0 (5.1–13.3) <0.001
Serum albumin (g/dl) 3.1 (2.7–3.7) 3.1 (2.7–3.7) 3.1 (2.7–3.8) n.s.
Serum CRP (mg/dl) 3.35 (0.98–8.98) 3.70 (1.08–10.0) 2.13 (0.20–6.70) n.s.
Proteinuria (g/day) 1.10 (0.35–2.12) 0.70 (0.30–1.77) 1.80 (1.10–2.50) <0.01
Data are expressed as mean ± SD or median (interquartile range). p values were calculated using the Mann–Whitney U test or Fisher’s exact test. Statistical
significance was defined as p < 0.05.
Abbreviations: ESRD end-stage renal disease, ns not significant, eGFR estimated glomerular filtration rate, MPO myeloperoxidase, PR3 proteinase-3, CRP C-reactive protein.
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no significant differences in age or gender among the four
classes. PR3-ANCA-positive patients occurred in the focal
class (n = 3) and the crescentic class (n = 2), but not in the
mixed or sclerotic class. Serum CRP was higher in the focal
and crescentic class than in the mixed and sclerotic class.
Proteinuria was lower in the focal class than in the other
three classes. The proportion of normal glomeruli was
higher in the mixed class than in the crescentic class,
but the proportion of sclerotic glomeruli was also
higher in the mixed class than in the crescentic class.
At the time of diagnosis, the median eGFRs in the focal,Table 2 Baseline characteristics of patients in each histopatho
Focal Crescen
Age (years) 66.1 ± 11.4 66.3 ± 1
Male/female, n 24/22 15/17
MPO-ANCA, n 40 26
PR3-ANCA, n 3 2
Both negative, n 3 4
eGFR (ml/min/1.73 m2) 38.1 (22.5–57.4) 12.0 (7.1–
Serum albumin (g/dl) 3.4 (2.8–3.7) 2.7 (2.4–
Serum CRP (mg/dl) 4.13 (1.43–9.62) 4.98 (1.65–
Proteinuria (g/day) 0.35 (0.21–0.79) 1.50 (1.04–
Immunosuppressants, yes/no, n 25/21 17/15
Histopathological findings
Normal glomeruli (%) 73.2 (60.0–81.6) 17.9 (10.6–
Crescentic glomeruli (%) 13.8 (8.9–23.6) 67.7 (60.0–
Globally sclerotic glomeruli (%) 6.5 (0–13.4) 3.2 (0–1
Data are expressed as mean ± SD or median (interquartile range).
Abbreviations: ns not significant, eGFR estimated glomerular filtration rate, MPO my
were administered after the diagnosis of ANCA-associated glomerulonephritis.
eGFR: focal vs. crescentic***, focal vs. mixed**, focal vs. sclerotic*, Serum albumin: focal v
sclerotic*, crescentic vs. mixed*, crescentic vs. sclerotic**, Proteinuria: focal vs. crescentic
Normal glomeruli: focal vs. crescentic***, focal vs. mixed***, focal vs. sclerotic***, Scleroti
Globally sclerotic glomeruli: focal vs. mixed***, focal vs. sclerotic***, crescentic vs. mixedcrescentic, mixed, and sclerotic class were 38.1, 12.0, 16.5,
and 12.4 ml/min/1.73 m2, respectively. eGFR was thus sig-
nificantly different in the focal class compared with the
other classes (p < 0.001 vs. crescentic; p < 0.01 vs. mixed;
p < 0.05 vs. sclerotic). However, there were no significant
differences among the crescentic, mixed, and sclerotic
class. One year after the initial diagnosis, the median
eGFRs were 45.7, 24.5, 26.0, and 16.9 ml/min/1.73 m2
in the focal, crescentic, mixed, and sclerotic class, respect-
ively. Except for patients who developed ESRD, eGFR at
1 year showed an improvement from that at diagnosis in
all four classes. Again, eGFR differed significantly betweenlogical class
tic Mixed Sclerotic p value





19.7) 16.5 (8.7–31.6) 12.4 (9.8–27.4) <0.0001
3.3) 3.1 (2.8–3.7) 3.8 (3.5–3.9) <0.01
14.0) 1.21 (0.10–3.93) 0.16 (0.10–1.10) <0.001
2.50) 1.75 (1.07–2.20) 1.50 (0.25–3.98) <0.0001
4/14 1/5 <0.05
28.0) 35.4 (22.5–43.8) 11.3 (0–22.0) <0.0001
74.7) 31.4 (15.6–40.4) 12.4 (3.3–22.4) <0.0001
3.1) 29.3 (19.0–40.4) 64.5 (54.9–71.1) <0.0001
eloperoxidase, PR3 proteinase-3, CRP C-reactive protein Immunosuppressants
s. crescentic*, crescentic vs. sclerotic**, Serum CRP: focal vs. mixed*, focal vs.
***, focal vs. mixed**, Immunosuppressants: focal vs. mixed*, crescentic vs. mixed*,
c glomeruli: focal vs. crescentic***, crescentic vs. mixed***, crescentic vs. sclerotic***,
***, crescentic vs. sclerotic***, *p< 0.05, **p < 0.01, ***p< 0.001.
Table 3 Proportions of ESRD according to the
histopathological classes
Class 1 year after diagnosis Total follow-up period
Focal 1/46 (2.2%) 2/46 (4.3%)
Crescentic 7/32 (21.9%) 9/32 (28.1%)
Mixed 2/18 (11.1%) 8/18 (44.4%)
Sclerotic 2/6 (33.3%) 4/6 (66.6%)
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centic; p < 0.05 vs. mixed; p < 0.01 vs. sclerotic), but there
were no significant differences among the crescentic,
mixed and sclerotic class (Figure 1).
At 1 year after initial diagnosis, SCr had doubled in
two patients, and another 10 patients had developed
ESRD. The incidences of these events combined at
1 year were 2.2% (1/46), 21.9% (7/32), 11.1% (2/18), and
33.3% (2/6) in the focal, crescentic, mixed, and sclerotic
class, respectively. During the entire follow-up period,
23 patients (22.5%) developed ESRD and 12 patients
died. Seven of the 12 patients who died developed
ESRD before death, and the remaining five died without
ESRD. The proportions of patients who developed ESRD
during follow up increased with sequential category, [focal,
4.3% (2/46); crescentic, 28.1% (9/32); mixed, 44.4% (8/18);
sclerotic, 66.6% (4/6); Table 3]. Kaplan-Meier analysis of
renal survival showed that prognosis was best for patients
in the focal class and worst for patients in the sclerotic
class (p < 0.001). Kaplan-Meier analysis found no signifi-
cant difference between the crescentic and mixed class
(p = 0.2716). However, the Kaplan-Meier renal survival
curve was almost similar to the curve of Berden et al. [9]
(Figure 2). In the multivariate Cox regression analysis,
the new classification system at diagnosis tended to be a
prognostic factor for ESRD during the follow-up period
(p = 0.0686, crescentic, mixed and sclerotic vs. focal, haz-
ard ratio (HR) [95% confidence interval, CI]; 2.99 [0.61–
22.7], 5.04 [1.11–36.4] and 9.93 [1.53–85.7], respectively).
Additionally, eGFR at diagnosis also tended to be a
prognostic factor for ESRD during the follow-up period
(p = 0.0619, HR [95% CI]; 0.97 [0.93–1.00]) (Table 4).
Analysis of the incidence of ESRD according to treat-
ment did not identify immunosuppressant use as a
prognostic factor for ESRD (p = 0.8390, HR [95%CI];
0.90 [0.31–2.45]). In addition, there was no significant
difference between patients treated with or without CYC
(data not shown).Figure 1 Association between histopathological class and eGFR. eG
focal class than in the other classes. There were no significant differenc
Abbreviations: eGFR, estimated glomerular filtration rate; blank circles, m
and ***p < 0.001 (post hoc analysis).Immunohistochemical study
Because histopathological evaluation by light micros-
copy could not differentiate the crescentic and mixed
class in terms of ESRD, we evaluated the ability of im-
munohistochemical studies to predict renal outcome.
We performed immunohistochemical staining for α-SMA,
WT1, CD68, and cytokeratin on samples from 34 patients
with crescentic or mixed class. There were no signifi-
cant differences in expression levels of WT1, CD68,
and cytokeratin between patients with and without
ESRD (data not shown). By contrast, α-SMA immuno-
reactivity differed substantially between each normal
glomerulus. As shown in Figure 3A, there was no im-
munoreactivity for α-SMA in this normal glomerulus,
except in the glomerular vascular pole and surround-
ing Bowman’s capsule. On the other hand, Figure 3B
shows marked immunoreactivity for α-SMA in a nor-
mal glomerulus. We counted the number of normal
glomeruli in each case and then assessed if they were
immunopositive for α-SMA or not. The mean propor-
tion of α-SMA-positive glomeruli per normal glom-
eruli was 82.9%. Receiver operating characteristics
analysis was used to identify the optimal cut-off rate
of α-SMA-positive glomeruli per normal glomeruli for
distinguishing renal outcome. A cut-off score of 83.3%
optimally identified 100% of ESRD cases (sensitivity)
and 46.7% of non-ESRD cases (specificity). In Kaplan-
Meier analysis, higher α-SMA expression tended to be
associated with poorer renal survival (Figure 3C).FRs at diagnosis and 1 year after diagnosis were higher in the
es in eGFR among the crescentic, mixed, and sclerotic class.
edian values; error bars, interquartile ranges. *p < 0.05, **p < 0.01,
Figure 2 Renal survival during follow up. Overall, 23/102 patients
developed ESRD during the total follow-up period. Renal survival
was best in the focal class and worst in the sclerotic class. There was
no significant difference between crescentic and mixed class
regarding renal survival.
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Clinical and histopathological findings
Several attempts have been made to establish histopatho-
logical criteria for ANCA-associated glomerulonephritis
and to predict ESRD and overall survival in this disease
[14,15]. However, studies investigating the clinical and
histopathological predictors of renal outcome have pro-
vided different results with some overlap, in terms of the
predictive values of normal glomeruli, glomerulosclerosis
and eGFR at diagnosis [4,5,16–19]. Most of the proposed
classification systems are cumbersome and require histo-
pathological evaluation as well as clinical information.
Berden et al. recently investigated the prognostic value of a
simple histopathological classification, based on an analysis
of 100 patients across multiple centers in Europe [9]. We
examined the suitability of this classification system for
Japanese patients with ANCA-associated glomeruloneph-
ritis. This histopathological classification was associated
with eGFR at 1 year in our cohort, as in Berden et al.’sTable 4 Multivariate analysis of progression to ESRD
Variable p value HR (95% CI)
Age 0.2336 1.03 (0.98–1.09)
Male 0.1072 2.33 (0.84–7.08)
eGFR at diagnosis 0.0619 0.97 (0.93–1.00)
Proteinuria at diagnosis 0.1059 1.23 (0.95–1.54)
Immunosuppressant, yes/no 0.8390 0.90 (0.31–2.45)
Histopathological
classification
0.0686 crescentic vs. focal, 2.99 (0.61–22.7)
mixed vs. focal, 5.04 (1.11–36.4)
sclerotic vs. focal, 9.93 (1.53–85.7)
Abbreviations: ESRD end-stage renal disease, HR hazard ratio,
CI confidence interval.study. The incidence of ESRD during the follow-up period
increased with sequential category of the proposed classifi-
cation. Although the Kaplan-Meier survival curves showed
the same distribution as the study by Berden et al., the his-
topathologic classification was not associated with ESRD
during follow up in our cohort in the multivariate analysis.
We think there are several possible explanations for why
we did not find an association between the classification
and developing ESRD. First, Berden et al.’s study was
conducted in Europe, and of the 100 patients, 45 were
positive for PR3-ANCA and 47 were positive for MPO-
ANCA. Notably, the distribution of ANCA subtypes in
Japanese patients with ANCA-associated vasculitis differs
from that in Western countries. For example, Japanese pa-
tients are more frequently positive for MPO-ANCA than
PR3-ANCA [10,11]. Indeed, our cohort consisted of 86 pa-
tients with MPO-ANCA-positive disease and just five with
PR3-ANCA-positive disease, while the remaining 11 pa-
tients were negative for both antibodies. The different dis-
tributions of MPO- and PR3-ANCA between Europe and
Japan may thus have contributed to the conflicting results.
However, we were unable to conclude if the mechanism of
glomerular injury was due to the different type of ANCA,
though patients with MPO-ANCA do show more active
and chronic lesions than PR3-ANCA patients [20]. In
addition, differences in genetic backgrounds may affect
the renal pathology findings and clinical courses in pa-
tients with ANCA vasculitis. International collaborative
studies are clearly needed to determine the causes of
the different phenotypes and clinical courses among
different populations.
A second possible reason for the apparent discrepancy
between the current results and those of Berden et al. [9]
may be the difference in treatments used in Europe and
Japan. In Europe, glucocorticoids in combination with
CYC or methotrexate is the standard therapeutic strategy
for ANCA-associated vasculitis [21], while in Japan, al-
though glucocorticoids in combination with CYC is also
recommended as a treatment for ANCA-associated vascu-
litis depending on the severity of disease, CYC is only used
in 33.7–45.2% of Japanese patients with ANCA-associated
systemic vasculitis [22]. CYC is used less frequently in
Japan to avoid associated events of infection, though its
low usage may also facilitate disease remission.
Age, sex, and eGFR at diagnosis have been reported to
be important predictors of renal outcome [5–8,18,23].
However, the current study found no significant differ-
ences in these factors at diagnosis between the cres-
centic and mixed class. Other reports have confirmed
the importance of normal glomeruli for better renal out-
come [6,8,18]. In our series, the proportion of normal
glomeruli was higher in the mixed class than in the cres-
centic class, but the proportion of sclerotic glomeruli
was also higher in the mixed class than in the crescentic
Figure 3 Comparison of renal survival according to α-SMA expression in crescentic and mixed classes. (A) Tissue section showing
absence of α-SMA staining in a normal glomerulus, except in the glomerular vascular pole and thickened Bowman’s capsule. (B) Tissue section
showing marked α-SMA expression in a normal glomerulus, suggesting activation of a mesangial cell. (C) Higher α-SMA positivity tended to be
associated with poor renal survival. Abbreviation: SMA, smooth muscle actin.
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between the crescentic and mixed class.
Several studies found that immune complex or com-
plement deposition in renal histopathology was associ-
ated with lower initial renal function, higher levels of
proteinuria and poor renal outcome [24–26]. In the
current study, only nine patients showed C3 deposition
in glomerular and/or arteriolar walls. The eGFR at diag-
nosis, proteinuria and incidence of ESRD in these nine
cases did not differ from those without C3, other im-
mune complex or complement deposition.
Immunohistochemical findings
There was no significant difference regarding the develop-
ment of ESRD between the crescentic and mixed class.
Therefore we performed immunohistochemical staining on
samples from 34 patients with crescentic or mixed class to
examine whether immunohistochemical factors are useful
to predict ESRD in ANCA-associated glomerulonephritis.
The rates of WT1, CD68, and cytokeratin expression did
not differ significantly between patients with or without
ESRD (data not shown). However, Kaplan-Meier analysis
demonstrated that higher α-SMA immunoreactivity tended
to be associated with poorer renal survival in crescentic
and mixed class.
Several studies have provided evidence to suggest that
glomerular component cells undergo mesenchymal tran-
sition in a pro-inflammatory environment. Epithelial-
mesenchymal transition (EMT) is widely accepted as a
mechanism whereby injured epithelial and/or endothe-
lial cells transform into mesenchymal cells, which con-
tribute to the development of fibrosis [27,28]. EMT and
myofibroblastic differentiation were originally thoughtto occur predominantly in the interstitium; however,
several reports have shown that mesangial cells can also
differentiate into myofibroblasts, resulting in fibrosis
[28,29]. Barnes et al. [30] reported that myofibroblasts
were mostly responsible for interstitial accumulation
and consequent structural deformations associated with fi-
brosis. In renal disease, glomerular mesangial cells also ac-
quire a myofibroblastic phenotype and synthesize the same
matrix proteins. α-SMA expression is considered to be a
useful marker of myofibroblast differentiation in several
disease settings [31–34]. We thought that a normal glom-
erulus under the light microscope might switch to a
fibrogenic state if the glomerulus was positive for α-SMA.
Notably, glomeruli often appeared normal under light
microscopy, but α-SMA positive or negative glomeruli
could be detected after careful observation. Conse-
quently, α-SMA-positive glomeruli may progress to fi-
brosis, glomerulosclerosis, and renal failure. However,
α-SMA positivity was not associated with renal survival. It
could be the low power of the α-SMA immunohistochemi-
cal analysis (n = 34), since the survival analysis did not
reach significance but came close to it (p = 0. 1074). There-
fore, further studies are needed to clarify whether immuno-
histochemical staining of α-SMA is a useful predictor for
renal prognosis.
This study had several limitations. First, the sample
size was relatively small, and this may have reduced the
validity of the results. Second, no standard therapy was
administered to all patients, and treatments were at the
discretion of the attending physicians. Third, immuno-
histochemical analysis was not performed in all cases
and we were therefore unable to perform Cox regression
multivariate analysis of the relationship between α-SMA
Iwakiri et al. BMC Nephrology 2013, 14:125 Page 8 of 9
http://www.biomedcentral.com/1471-2369/14/125positivity and ESRD. Fourth, the association between the
histopathologic classification system and eGFR at 1 year
was only based on an univariate analyses. Multivariate ana-
lysis with eGFR at 1 year as outcome was not performed.
Finally, this current study was a retrospective study, thus
further verification by a prospective study is desired.
Conclusions
The histopathological classification system proposed by
Berden et al. [9] is a simple method, which is associ-
ated with eGFR at 1 year and tends to be associated
with the incidence of ESRD in Japanese patients with
ANCA-associated glomerulonephritis in our cohort.
α-SMA immunopositivity shows a trend toward an as-
sociation with the renal survival rates of patients classi-
fied as crescentic or mixed class. Therefore, we suggest
that immunohistochemical staining for α-SMA expres-
sion, a widely used pathological method, might be use-
ful to estimate renal outcome. Further verification of
the histopathologic classification and α-SMA staining
for ANCA-associated glomerulonephritis is desired.
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